Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals.

Biosyngen, an innovative biotechnology company specializing in immune cell therapies, is presenting its groundbreaking "Conditional Activation + Armor Enhancement" T-cell technology at this year's ESMO conference.

Biosyngen has secured ten clinical trial approvals in China and the U.S. for its innovative fourth-generation oncology therapies. Currently, our leading pipeline product, BRG01, is in the pivotal Phase II clinical trial stage for solid tumors. Additionally, the first patients have been enrolled in the Phase I trials for our other groundbreaking therapies, BST02 and BRL03, with completion of Phase I trials anticipated later this year.

Abstract Title
Anti-tumor Efficacy and Safety of Conditionally Activated Armored CAR-T Cells against Gastrointestinal Tumor

Title No.
1033P

Gastrointestinal tumors have been found to exhibit significantly elevated levels of tumor-associated antigens (TAAs) compared to normal tissues, presenting potential targets for immune cell therapies. However, these TAAs are also expressed at certain levels in normal tissues, which poses a challenge for CAR-T cell therapies. Current CAR-T cells often fail to distinguish between tumor and normal tissues, leading to damage to normal organs and adverse clinical reactions. This on-target off-tumor toxicity not only raises safety concerns in clinical treatment but also limits dosage and efficacy enhancement.

To overcome this technical challenge and balance safety with efficacy in solid tumor immune cell therapies, Biosyngen has developed the SUPER-T™ T cell safety optimization platform and created the Conditional Activation CAR-T cell BTRP003L. This technology allows CAR-T cells to activate only under hypoxic conditions typical of the tumor microenvironment (0.3% ~ 2.0% O2), while remaining inactive in normal tissues (3.4% ~ 6.8% O2). Remarkably, this approach not only regulates CAR-T cell activation levels under different conditions effectively but also enhances their antitumor capabilities (Figure 1). Further advancements include the co-expression of a TGFβRII dominant-negative mutant, resulting in the "Conditional Activation + Armor Enhancement" CAR-T cell BTRP011L, which shows improved efficacy and in vivo persistence at lower doses (Figure 2). Toxicology studies using the SUPER-T™ platform showed no weight loss or other adverse effects in mice injected with BTRP003L or BTRP011L, demonstrating robust safety (Figure 3).

About Biosyngen's Innovative Technology Platforms

Identifier™ Platform: A drug discovery platform providing a solid foundation for the discovery of antigens, antibodies, and TCRs. With a database of hundreds of TCRs and tumor proteins, this platform supports rapid screening and optimization, identifying the most unique and suitable tumor antigens. This platform serves as a pioneer. As the ancients said, "Before troops are mobilized, provisions must be in place," which is precisely why the Identifier™ platform exists — to obtain the necessary "provisions" more rapidly.

MSE-Tâ„¢ Platform: A T-cell function enhancement platform that improves the ability of immune cells to recognize tumor-specific antigens and overcome the immunosuppressive tumor microenvironment, thereby more effectively in treating difficult-to-treat solid tumors.

SUPER-Tâ„¢ Platform: A T-cell safety optimization platform that enhances the safety of immunotherapy through conditional activation in the tumor microenvironment. This platform ensures maximum safety for the drug.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

VISTA, Calif., Sept. 19, 2024 /PRNewswire/ -- NUZEE, INC., ("NUZEE"or the "Company") (NASDAQ：NUZE) a Company with a heritage in specialty coffee and an emerging business in broader consumer food and beverage products, today announced that the Company has signed an endorsement agreement with five sports champions who will endorse the maca beverages (the "Macanuoli") distributed and sold by the Company (the "Agreement"). The five sport champions are Ms. Shurui Li, women's basketball champion; Ms. Chenlin Zhou, trampoline champion; Ms. Lina Yi, tennis champion; Ms. Bingjian Li, bodybuilding champion; and Ms. Shuna Bai, cheerleading champion (the "Sport Champions"). The term of the Agreement between the Company and the Sports Champions is one year (the "Cooperation Period").

According to the Agreement, the images of the Sport Champions can be used for the Macanuoli's packaging, advertisement and public relations activities during the Cooperation Period.

Macanuoli is the first plant-based energy drink launched by NUZEE. Macanuoli's ingredients include plant extracts such as maca and Noni which help relieve physical fatigue, and enhancing immunity. Macanuoli is ideal for people who pursue safe, healthy, and natural food.

Ms. Jianshuang Wang, the Chief Executive Officer of NUZEE, commented, "The cooperation between the Company and the Sport Champions is the first marketing event of Macanoli Beverage in the market, and we hope to increase market awareness of our Macanuoli product. We also hope to convey positive sportsmanship attitudes through Macanuoli, advocate for a healthy lifestyle, and grow together with consumers."

About NUZEE, INC.

NUZEE, INC. is a digital marketing, sales and distribution company for various consumer products with focuses on food and beverages. Dedicated to reshaping the digital marketing and distribution with technological applications, the Company endeavors to create greater commercial value for its business partners and therefore enhance its own enterprise value and shareholders' value of their stake in the Company. The Company has a professional brand and marketing management system, which can quickly help partnering enterprises achieve their connection, management, and operation of marketing channels domestically and globally.

Forward-Looking Statements

This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary for its operations, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.

For more information, please contact:
http://www.nuzee.vip 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Nuzee, Inc. Announces Endorsement Agreement Between Macanuoli and Five Sports Champions